Public company intelligence preview
BIOLIFE SOLUTIONS INC
118 insider trades surfaced from the last year. This page shows only aggregate signals, not the underlying transactions, people, filings, filters, or AI workspace.
Snapshot
A narrow read on a much deeper workspace.
The preview gives search visitors enough signal to understand coverage. It does not expose transaction records, person-level profiles, filters, comparisons, or analyst workflows.
Insider compensation
Public aggregate: $1.8M average total compensation across covered insiders.
Governance movement
Public aggregate: 1 governance events in the last year.
Institutional ownership
Public aggregate: 184 holders from the latest quarter.
Restricted sales and governance
Public counts, not the investigation layer.
The full product opens the underlying filings, insider context, historical holdings, comparison tools, and AI analysis.
Market context
Basic quote context for the preview.
Company note
Context before the data.
Company Overview
BioLife Solutions Inc. operates in the Healthcare sector and the Medical Instruments & Supplies industry, with a business centered on bioproduction tools for the cell and gene therapy ecosystem. Its products include biopreservation media, thawing devices, containers, and related workflow technologies that help customers improve cell viability, reduce contamination risk, and support manufacturing and delivery of biologic therapies. Recent filings show strong demand recovery, with 2025 revenue growth driven by customers with commercially approved therapies and improved ordering patterns after prior destocking. The company also has a meaningful U.S.-centric footprint, with manufacturing in Washington and Indiana and a global customer base concentrated in the United States.
Executive Compensation Practices
Executive compensation at BioLife Solutions is likely shaped by a mix of revenue growth, gross margin performance, operating cash flow, and strategic execution, rather than simple top-line expansion alone. The 2025 filings show that stock-based compensation, severance, acquisition-related costs, and R&D headcount growth were significant contributors to operating expense increases, suggesting equity awards are an important part of pay and may be tied to long-term value creation. In this Medical Instruments & Supplies business, compensation metrics may also emphasize commercial adoption of biopreservation media, margin stability, product mix, and successful integration of acquisitions such as PanTHERA. Because the company continues to carry a valuation allowance and faces impairment, earnout, and integration risks, incentive plans may also reflect milestone-based or retention-oriented structures to keep management focused on execution.
Insider Trading Considerations
Insider trading patterns at BioLife Solutions may be influenced by the volatility of demand in the cell and gene therapy market, where customer ordering, safety-stock changes, and quarter-end pull-forwards can materially affect results. Executives may be especially sensitive to blackout periods around earnings, acquisition announcements, divestitures, and updates on strategic initiatives like PanTHERA integration or the SAVSU sale. Since the business depends on intellectual property, regulatory-supporting documentation, and supply-chain stability, insiders may react to developments involving product launches, manufacturing yields, inventory reserves, or customer concentration. For a company in the Medical Instruments & Supplies industry, insiders may also be cautious about trading ahead of margin updates, R&D progress, and any signs of revenue variability tied to biotech funding conditions or customer commercialization timelines.
Unlock the full BLFS insider intelligence workspace.
Move from public aggregate counts into transaction-level detail, people, filings, compensation history, ownership shifts, export tools, and AI-assisted analysis.